The Human Genome Project took $1 billion and thirteen years. Science was left with the first draft of the human genome, and an eventual reversal of the scientific method: a fascination with letting data tell the story first. There existed a sentiment that if the industry could gather all available genomic, DNA sequencing, electronic health record and insurance claim data, a complete understanding of human biology would result. It seems each biotechnology company, every hospital system and all payers must boast of their big data initiatives, their artificial intelligence aspirations and their population health predictive analytics to remain relevant. The biotechnology industry is predictably excited, but has the potential of big data initiatives in healthcare been over-promised? How do we separate hype from reality? What can and is being done, and what is simply big data hubris? It seems biotechnology is drowning in its own data—how will it swim?

Ability Level: All

Session ID: 21077